Targeting a healthy future

Precision. Oncology. Targeted.

About Point Biopharma

Founded in late 2019, POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer.

Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.

What are Radio Ligands?

Radioligands are safe and effective cancer treatments that have been used for many years to diagnose and treat cancers such as non-Hodgkins lymphoma, neuroendocrine tumours, thyroid cancer and, most recently, prostate cancer.

Compared to chemotherapy, which can cause extensive damage to healthy cells, radioligands precisely deliver a radioactive payload that kills cancer cells and leaves surrounding healthy cells untouched. The immune system is then mobilized to the site of disease, amplifying the therapeutic effect.

Our objective is to provide the right medicine at the right time for the right patient. By combining radioligands with companion molecular imaging agents and PET/CT, physicians can make informed treatment decisions and select patients that will respond to treatment for the best outcomes.

Investors and Partners

POINT Biopharma has developed deep expertise in radiopharmaceutical trials, manufacturing and commercial deployment. We continue to look for assets and partners with unique expertise and innovative platforms.

News

Join our newsletter to stay up-to-date:

Executive Team

Dr. Joe McCann

Chief Executive Officer

Dr. McCann has overall responsibility for the day-to-day operations of POINT. Prior to taking on this role, Dr. McCann was CEO of Centre for Probe Development and Commercialization (CPDC) where he led the organization through development and validation of 17 different imaging probe and radiotherapeutic programs, used in national and international clinical trials. Prior to joining CPDC, Dr. McCann was a Scientist in Pharmaceutical Development at GlaxoSmithKline, responsible for developing products across all stages of clinical development. Dr. McCann has a Ph.D. in biochemistry from McMaster University.

Todd Hockemeyer

EVP of US Manufacturing Ops.

Todd Hockemeyer is responsible for the US manufacturing operations for POINT. Prior to taking on this role, Todd led the construction and operations of a full-scale commercial radiopharmaceutical manufacturing facility at Radiomedix and was previously head of Zevacor’s quality and regulatory affairs team. An industrial engineer, with operations and manufacturing expertise spanning over 25 years, Todd has significant expertise in radiopharmaceutical manufacturing, quality systems and regulatory affairs.

Michael Gottlieb

Chief Commercial Officer

Michael is responsible for commercial operations, market strategy and patient focused engagement. Prior to joining, Michael spent 7 years at Sanofi Genzyme Canada leading Commercial Operations, Patient infusions and support programs, Strategy, Finance, and most recently as the Rare Disease Franchise Head responsible for sales and marketing across a broad portfolio of orphan drug and oncology products. While in this role, Michael led teams responsible for physician and patient engagement, market access, and pricing. Michael is a Chartered accountant and CPA.

Allan Silber

Executive Chairman

Allan C. Silber is the Chairman of Point Biopharma. He is also chairman of Verity Pharmaceuticals, a specialty pharmaceutical company and also chairs Heritage Global Inc., a global financial services and asset trading company providing corporate and financial asset monetization, advisory, and valuation services. Mr. Silber has an extensive background in the private equity, real-estate and financial services fields. Mr. Silber is the former CEO of Street Capital Group Inc. and Counsel Corporation.

Dr. Neil Fleshner

Chief Medical Officer

Dr. Neil Fleshner graduated with a medical degree from the University of Toronto in 1988. He completed specialty training in urologic surgery and oncology from 1993 to 1996, received a Master’s in Public Health in epidemiology from Columbia University in 1997, and completed his oncology training at Memorial Sloan-Kettering Cancer Center. Dr. Fleshner is certified in both urology and epidemiology. Dr. Fleshner is also a Professor of Surgery at the University of Toronto, and also holds the prestigious Love Chair in prostate cancer prevention at Princess Margaret Hospital.

Howard Glase

Board Member

Howard brings over twenty years of Canadian and U.S. corporate pharmaceutical senior commercial management experience to POINT and is the CEO fo Verity Pharmaceuticals. Howard has also gained experience as a CEO within the medical market research and scientific communications industries.

Acquired corporate pharmaceutical brand experiences include the launch of Cipro in Canada and Cipro IV for global markets. Additionally, Howard launched Cardizem CD in Canada and moved to the national commercial team in the USA (Sanofi) on the cardiovascular portfolio, with national responsibilities on Cardizem CD ($1.3 billion in sales) and led the launch of Teczem (Co-promoted with Merck) in the American hypertension market.